Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.

Medtronic received the FDA approval for its recharge-free Implantable Neurostimulator, Vanta Spinal Cord Stimulation (SCS), with a device life optimizable up to 11 years. The company has surely set the benchmark in the recharge-free medical devices market with its device proving to be much more convenient than the other rechargeable SCS devices that demanded replacement within a few years. However, the device is expected to face stiff competition from other players in the market including Boston Scientific, Abbott, and others.